SG11201805385QA - Bromodomain and extra-terminal protein inhibitor combination therapy - Google Patents
Bromodomain and extra-terminal protein inhibitor combination therapyInfo
- Publication number
- SG11201805385QA SG11201805385QA SG11201805385QA SG11201805385QA SG11201805385QA SG 11201805385Q A SG11201805385Q A SG 11201805385QA SG 11201805385Q A SG11201805385Q A SG 11201805385QA SG 11201805385Q A SG11201805385Q A SG 11201805385QA SG 11201805385Q A SG11201805385Q A SG 11201805385QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- bromodomain
- extra
- bet
- combination therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 29 June 2017 (29.06.2017) WIPOIPCT (10) International Publication Number WO 2017/112703 A1 (51) International Patent Classification: A61P 35/00 (2006.01) A ft IK 9/00 (2006.01) A61K 31/337 (2006.01) G01N 33/574 (2006.01) (21) International Application Number: PCT/US2016/067860 (22) International Filing Date: 20 December 2016 (20.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/387,359 24 December 2015 (24.12.2015) US 62/413,763 27 October 2016 (27.10.2016) US (71) Applicant: CELGENE QUANTICEL RESEARCH, INC. [US/US]; 9393 Towne Centre Drive, Suite 110, San Diego, California 92121 (US). (72) Inventors: NIKOLOVA, Zariana; c/o Celgene Interna tional Sari, Route de Perreaux 1, 2017 Boudry (CH). CHO, Robert; 1585 Riorden Terrace, Sunnyvale, Califor nia 94087 (US). STAFFORD, Jeffrey Alan; 12752 Sandy Crest Court, San Diego, California 92130 (US). (74) Agents: SUNG, Lawrence M. et al.; Wiley Rein LLP, Pat ent Administration, 1776 K Street, NW, Washington, Dis trict of Columbia 20006 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: BROMODOMAIN AND EXTRA-TERMINAL PROTEIN INHIBITOR COMBINATION THERAPY FIG. 8 o i> CJ 2500 ro £ 200 | 1500 :> £ IOOO c S 500 0 10 15 Days of Treatment 20 o CJ (57) : The present disclosure relates generally to compositions and methods of treating cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising the administra tion of a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination therapy can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared to the administration of either the BET inhibitor or the chemotherapeutic agent alone.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387359P | 2015-12-24 | 2015-12-24 | |
| US201662413763P | 2016-10-27 | 2016-10-27 | |
| PCT/US2016/067860 WO2017112703A1 (en) | 2015-12-24 | 2016-12-20 | Bromodomain and extra-terminal protein inhibitor combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805385QA true SG11201805385QA (en) | 2018-07-30 |
Family
ID=59087538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805385QA SG11201805385QA (en) | 2015-12-24 | 2016-12-20 | Bromodomain and extra-terminal protein inhibitor combination therapy |
| SG10202013249PA SG10202013249PA (en) | 2015-12-24 | 2016-12-20 | Bromodomain and extra-terminal protein inhibitor combination therapy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202013249PA SG10202013249PA (en) | 2015-12-24 | 2016-12-20 | Bromodomain and extra-terminal protein inhibitor combination therapy |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20170182025A1 (en) |
| EP (1) | EP3393586A4 (en) |
| JP (1) | JP2019503358A (en) |
| KR (1) | KR20180095935A (en) |
| CN (1) | CN108883311A (en) |
| AU (1) | AU2016379347A1 (en) |
| BR (1) | BR112018013063A2 (en) |
| CA (1) | CA3009642A1 (en) |
| CL (1) | CL2018001724A1 (en) |
| EA (1) | EA201891514A1 (en) |
| IL (1) | IL260222A (en) |
| MX (1) | MX2018007823A (en) |
| SG (2) | SG11201805385QA (en) |
| TW (1) | TW201733576A (en) |
| WO (1) | WO2017112703A1 (en) |
| ZA (1) | ZA201804223B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3532059T3 (en) | 2016-10-27 | 2022-03-14 | Celgene Quanticel Res Inc | COMBINATION THERAPY WITH BROMDOMAIN AND EXTRA TERMINAL PROTEIN INHIBITOR |
| US11332466B2 (en) | 2017-12-01 | 2022-05-17 | The Board Of Trustees Of The University Of Illinois | Pyridinone-based epigenetic modifiers and uses thereof |
| WO2019204758A1 (en) * | 2018-04-20 | 2019-10-24 | Zhiguo Zhang | Compositions and methods for treating glioblastoma by modulating a mgmt enhancer |
| CN109001638B (en) * | 2018-06-22 | 2020-12-29 | 格林美（无锡）能源材料有限公司 | Method for rapidly evaluating DCR before and after coating of positive electrode material |
| CN112823152A (en) * | 2018-07-23 | 2021-05-18 | 赛尔基因昆蒂赛尔研究公司 | Methods for preparing bromodomain inhibitors |
| WO2020169698A1 (en) * | 2019-02-21 | 2020-08-27 | F. Hoffmann-La Roche Ag | Sensitization of cancer cells to tnf by bet inhibition |
| US20230035892A1 (en) * | 2019-09-03 | 2023-02-02 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating cancer |
| CN111930838B (en) * | 2020-07-23 | 2023-05-16 | 金陵科技学院 | Time-oriented distributed archive management method |
| CA3237530A1 (en) * | 2021-11-15 | 2023-05-19 | The Board Of Trustees Of The University Of Illinois | Method of treating cancer associated with a ras mutation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6189951B2 (en) * | 2012-07-13 | 2017-08-30 | ベクトン ディキンソン アンド カンパニー リミテッド | Medical vial access device with pressure equalization and closed drug delivery system |
| US9073878B2 (en) * | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| CA2895905A1 (en) * | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
| TWI527811B (en) * | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | Benzimidazole derivatives as bromodomain inhibitors |
| JP6461121B2 (en) * | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | Novel bicyclic bromodomain inhibitors |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| DK3640241T3 (en) * | 2013-10-18 | 2022-11-28 | Celgene Quanticel Res Inc | BROMO DOMAIN INHIBITORS |
| US20150320754A1 (en) * | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
-
2016
- 2016-12-20 SG SG11201805385QA patent/SG11201805385QA/en unknown
- 2016-12-20 BR BR112018013063A patent/BR112018013063A2/en not_active Application Discontinuation
- 2016-12-20 JP JP2018532625A patent/JP2019503358A/en active Pending
- 2016-12-20 EA EA201891514A patent/EA201891514A1/en unknown
- 2016-12-20 KR KR1020187021390A patent/KR20180095935A/en unknown
- 2016-12-20 US US15/385,763 patent/US20170182025A1/en not_active Abandoned
- 2016-12-20 AU AU2016379347A patent/AU2016379347A1/en not_active Abandoned
- 2016-12-20 MX MX2018007823A patent/MX2018007823A/en unknown
- 2016-12-20 CN CN201680082656.XA patent/CN108883311A/en active Pending
- 2016-12-20 CA CA3009642A patent/CA3009642A1/en not_active Abandoned
- 2016-12-20 WO PCT/US2016/067860 patent/WO2017112703A1/en active Application Filing
- 2016-12-20 SG SG10202013249PA patent/SG10202013249PA/en unknown
- 2016-12-20 EP EP16879991.4A patent/EP3393586A4/en not_active Withdrawn
- 2016-12-23 TW TW105142897A patent/TW201733576A/en unknown
-
2018
- 2018-06-22 ZA ZA2018/04223A patent/ZA201804223B/en unknown
- 2018-06-22 CL CL2018001724A patent/CL2018001724A1/en unknown
- 2018-06-24 IL IL260222A patent/IL260222A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20170182025A1 (en) | 2017-06-29 |
| TW201733576A (en) | 2017-10-01 |
| SG10202013249PA (en) | 2021-02-25 |
| JP2019503358A (en) | 2019-02-07 |
| KR20180095935A (en) | 2018-08-28 |
| CA3009642A1 (en) | 2017-06-29 |
| CN108883311A (en) | 2018-11-23 |
| WO2017112703A1 (en) | 2017-06-29 |
| EA201891514A1 (en) | 2019-01-31 |
| ZA201804223B (en) | 2019-09-25 |
| EP3393586A1 (en) | 2018-10-31 |
| EP3393586A4 (en) | 2019-07-17 |
| CL2018001724A1 (en) | 2018-11-16 |
| MX2018007823A (en) | 2018-11-09 |
| IL260222A (en) | 2018-07-31 |
| AU2016379347A1 (en) | 2018-07-12 |
| BR112018013063A2 (en) | 2018-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805385QA (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201810171SA (en) | Kras g12c inhibitors | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201806110QA (en) | Treatment of cancer with combinations of immunoregulatory agents | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201808913WA (en) | Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy |